National Vision (EYE)
(Delayed Data from NSDQ)
$13.20 USD
-0.38 (-2.80%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $13.20 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
National Vision (EYE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.75 | $28.00 | $16.00 | 60.16% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for National Vision comes to $21.75. The forecasts range from a low of $16.00 to a high of $28.00. The average price target represents an increase of 60.16% from the last closing price of $13.58.
Analyst Price Targets (8 )
Broker Rating
National Vision currently has an average brokerage recommendation (ABR) of 2.30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 2.30 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, four are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.30 | 2.30 | 2.30 | 2.30 | 2.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/10/2024 | Not Identified | Not Identified | Hold | Hold |
5/8/2024 | UBS | Michael L Lasser | Not Available | Strong Buy |
5/1/2024 | Not Identified | Not Identified | Hold | Hold |
4/30/2024 | William Blair | Dylan Carden | Strong Buy | Strong Buy |
2/28/2024 | Goldman Sachs | Katharine A Mcshane | Hold | Hold |
2/28/2024 | Loop Capital Markets | Anthony C Chukumba | Strong Buy | Strong Buy |
1/4/2024 | Wells Fargo Securities | Zachary Fadem | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.30 |
ABR (Last week) | 2.30 |
# of Recs in ABR | 10 |
Average Target Price | $21.75 |
LT Growth Rate | 14.10% |
Industry | Medical - Products |
Industry Rank by ABR | 101 of 253 |
Current Quarter EPS Est: | 0.06 |